CVRx (NASDAQ:CVRX) Upgraded to Strong-Buy at William Blair

William Blair upgraded shares of CVRx (NASDAQ:CVRX - Free Report) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports. William Blair also issued estimates for CVRx's Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($2.00) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.39) EPS and FY2026 earnings at ($1.96) EPS.

A number of other equities research analysts also recently commented on CVRX. Lake Street Capital decreased their target price on CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. Piper Sandler decreased their target price on CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $7.00 target price (down previously from $15.00) on shares of CVRx in a report on Friday, May 9th. Finally, Canaccord Genuity Group decreased their target price on CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.50.

CVRx Stock Down 1.9%

Shares of CVRX stock traded down $0.13 during trading hours on Monday, reaching $6.83. 111,973 shares of the company's stock were exchanged, compared to its average volume of 305,075. CVRx has a 1 year low of $4.30 and a 1 year high of $18.55. The stock has a market cap of $178.06 million, a PE ratio of -3.13 and a beta of 1.23. The company has a current ratio of 14.82, a quick ratio of 13.45 and a debt-to-equity ratio of 0.71. The stock's fifty day moving average price is $6.37 and its two-hundred day moving average price is $10.27.

CVRx (NASDAQ:CVRX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.03. CVRx had a negative return on equity of 79.04% and a negative net margin of 97.49%. The firm had revenue of $12.35 million during the quarter, compared to the consensus estimate of $14.68 million. Research analysts predict that CVRx will post -1.91 EPS for the current year.

Insider Transactions at CVRx

In related news, Director Kirk G. Nielsen purchased 61,200 shares of the firm's stock in a transaction on Wednesday, May 14th. The stock was bought at an average cost of $5.23 per share, with a total value of $320,076.00. Following the completion of the acquisition, the director owned 1,899,168 shares of the company's stock, valued at $9,932,648.64. The trade was a 3.33% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders purchased 78,666 shares of company stock valued at $411,031 over the last three months. Insiders own 13.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in CVRx by 10,520.1% in the fourth quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock valued at $7,960,000 after acquiring an additional 622,370 shares during the period. Wells Fargo & Company MN increased its position in shares of CVRx by 86.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,894 shares of the company's stock valued at $113,000 after buying an additional 4,115 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of CVRx in the fourth quarter valued at approximately $455,000. Bank of America Corp DE increased its position in shares of CVRx by 13.9% in the fourth quarter. Bank of America Corp DE now owns 103,207 shares of the company's stock valued at $1,308,000 after buying an additional 12,600 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of CVRx by 1,469.3% in the first quarter. GAMMA Investing LLC now owns 4,598 shares of the company's stock valued at $56,000 after buying an additional 4,305 shares in the last quarter. 75.27% of the stock is owned by institutional investors and hedge funds.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.